A first-in-human clinical trial for a prion disease candidate began enrolling patients, marking a milestone for a fatal neurodegenerative area with limited options. The Phase 1 study will evaluate safety, tolerability, and dosing for a divalent siRNA therapy intended to target prion disease mechanisms. In neonatology, a report connected neonatal sepsis to long-term lung function impairment in preterm children, linking early-life infection with respiratory outcomes that can persist into school age. The data adds to the evidence base supporting tighter infection surveillance and more robust follow-up for preterm survivors. Separately, a quality improvement effort reduced neonatal packed red blood cell transfusion frequency, with the study presented as an actionable NICU operational change. Together, these updates reflect an ongoing mix of translational therapeutics and bedside process improvements aimed at reducing high-burden morbidity in early-life populations.